Patents by Inventor Winifred W. Prosise
Winifred W. Prosise has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210317215Abstract: The invention provides methods for producing crystalline an anti-PD-1 monoclonal antibody (mAb), wherein the mAb is pembrolizumab or a pembrolizumab variant, comprising (1) mixing a solution comprising (a) the mAb, (b) polyethylene glycol (PEG), and (c) an additive selected from the group consisting of: caffeine, theophylline, 2? deoxyguanosine-5?-monophosphate, a bioactive gibberellin, and a pharmaceutically acceptable salt of said bioactive gibberellin, to form a crystallization solution, (2) incubating the crystallization solution for a period of time sufficient for crystal formation; and (3) optionally harvesting the crystalline anti-PD-1 mAb from the solution. In specific embodiments, the PEG is PEG 3350 and the additive is caffeine. The invention also relates to the novel anti-human PD-1 mAb crystals produced by the methods described herein.Type: ApplicationFiled: October 28, 2019Publication date: October 14, 2021Applicant: Merck Sharp & Dohme Corp.Inventors: Paul Reichert, Winifred W. Prosise, Xiaoyu Yang, Corey Strickland, Chakravarthy Nachu Narasimhan, Thierry O. Fischmann, Erika R. Walsh, Yongchao Su
-
Patent number: 11014986Abstract: Crystals of pembrolizumab and structurally similar anti-PD-1 monoclonal antibodies are provided, as well as methods of producing such crystals, and uses of compositions comprising such antibody crystals, e.g. in treatment of cancers. The present invention satisfies these needs and more by providing pembrolizumab crystals and a method producing pembrolizumab crystals. One embodiment of the method of the invention produces crystals suitable for X-ray diffraction, and the inventors herein used such crystals to solve the three-dimensional structure of pembrolizumab to 2.3 A resolution.Type: GrantFiled: February 22, 2016Date of Patent: May 25, 2021Assignee: Merck Sharp & Dohme Corp.Inventors: Paul Reichert, Winifred W. Prosise, Giovanna Scapin, Xiaoyu Yang, Ramesh Kashi, Corey Strickland
-
Publication number: 20200131272Abstract: The present invention relates to anti-CD27 antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.Type: ApplicationFiled: December 23, 2019Publication date: April 30, 2020Applicants: Merck Sharp & Dohme Corp., Merck Sharp & Dohme B.V.Inventors: Amy M. Beebe, Jason Ka Jen Cheung, Veronica Juan, Laurence Fayadat-Dilman, Svetlana Sadekova, Jerelyn Wong, Hans van Eenennaam, Andrea van Elsas, Lars Guelen, Thierry Olivier Fischmann, Winifred W. Prosise
-
Patent number: 10556957Abstract: The present invention relates to anti-CD27 antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.Type: GrantFiled: September 25, 2017Date of Patent: February 11, 2020Assignees: Merck Sharp & Dohme Corp., Merck Sharp & Dohme B. V.Inventors: Amy M. Beebe, Jason Ka Jen Cheung, Veronica Juan, Laurence Fayadat-Dilman, Svetlana Sadekova, Jerelyn Wong, Hans van Eenennaam, Andrea van Elsas, Lars Guelen, Thierry Olivier Fischmann, Winifred W. Prosise
-
Publication number: 20190300618Abstract: The present invention relates to anti-CD27 antibodies, as well as use antibodies in the treatment of diseases such as cancer and infectious disease.Type: ApplicationFiled: September 25, 2017Publication date: October 3, 2019Applicants: Merck Sharp & Dohme Corp., Merck Sharp & Dohme B.V.Inventors: Amy M. Beebe, Jason Ka Jen Cheung, Veronica Juan, Laurence Fayadat-Dilman, Svetlana Sadekova, Jerelyn Wong, Hans van Eenennaam, Andrea van Elsas, Lars Guelen, Thierry Olivier Fischmann, Winifred W. Prosise
-
Publication number: 20180237524Abstract: Crystals of pembrolizumab and structurally similar anti-PD-1 monoclonal antibodies are provided, as well as methods of producing such crystals, and uses of compositions comprising such antibody crystals, e.g. in treatment of cancers. The present invention satisfies these needs and more by providing pembrolizumab crystals and a method producing pembrolizumab crystals. One embodiment of the method of the invention produces crystals suitable for X-ray diffraction, and the inventors herein used such crystals to solve the three-dimensional structure of pembrolizumab to 2.3 A resolution.Type: ApplicationFiled: February 22, 2016Publication date: August 23, 2018Applicant: Merck Sharp & Dohme Corp.Inventors: Paul Reichert, Winifred W. Prosise, Giovanna Scapin, Xiaoyu Yang, Ramesh Kashi, Corey Strickland
-
Publication number: 20180086841Abstract: The present invention relates to anti-CD27 antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.Type: ApplicationFiled: September 25, 2017Publication date: March 29, 2018Applicants: Merck Sharp & Dohme Corp., Merck Sharp & Dohme B.V.Inventors: Amy M. Beebe, Jason Ka Jen Cheung, Veronica Juan, Laurence Fayadat-Dilman, Svetlana Sadekova, Jerelyn Wong, Hans van Eenennaam, Andrea van Elsas, Lars Guelen, Thierry Olivier Fischmann, Winifred W. Prosise
-
Patent number: 9803010Abstract: Crystalline forms of antibodies to human IL-23, such as antibodies to human IL-23p19 , are provided, as well as methods of producing such crystalline forms, and uses of such crystalline forms, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders. In various embodiments, the anti-hulL-23 antibody crystals, such as anti-hulL-23p19 antibody crystals of the present invention are obtainable by batch crystallization methods, vapor diffusion methods, liquid-liquid diffusion methods, and dialysis. In other aspects, the invention relates to suspensions of the crystalline anti-hulL-23 antibodies of the present invention, including those at higher concentrations and lower viscosities than would be possible with a corresponding non-crystalline solution at the same concentration of antibody. In other embodiments, the anti-huiL-23 antibody crystals of the present invention have increased stability, i.e.Type: GrantFiled: June 25, 2013Date of Patent: October 31, 2017Assignee: Merck Sharp & Dohme Corp.Inventors: Paul Reichert, Winifred W. Prosise, Peter Orth, Chakravarthy Nachu Narasimhan, Ramesh S. Kashi
-
Publication number: 20150147337Abstract: Crystalline forms of antibodies to human IL-23, such as antibodies to human IL-23p19, are provided, as well as methods of producing such crystalline forms, and uses of such crystalline forms, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders. In various embodiments, the anti-hulL-23 antibody crystals, such as anti-hulL-23p19 antibody crystals of the present invention are obtainable by batch crystallization methods, vapor diffusion methods, liquid-liquid diffusion methods, and dialysis. In other aspects, the invention relates to suspensions of the crystalline anti-hulL-23 antibodies of the present invention, including those at higher concentrations and lower viscosities than would be possible with a corresponding non-crystalline solution at the same concentration of antibody. In other embodiments, the anti-huiL-23 antibody crystals of the present invention have increased stability, i.e.Type: ApplicationFiled: June 25, 2013Publication date: May 28, 2015Applicant: Merck Sharp & Dohme Corp.Inventors: Paul Reichert, Winifred W. Prosise, Peter Orth, Chakravarthy Nachu Narasimhan, Ramesh S. Kashi
-
Patent number: 7785879Abstract: The present invention relates, inter alia, to PXR polypeptides and crystals that are useful, for example, for crystallization and in assays for identification of modulators of PXR.Type: GrantFiled: September 18, 2006Date of Patent: August 31, 2010Assignee: Schering CorporationInventors: Wenyan Wang, Shahriar Shane Taremi, Winifred W. Prosise, Paul Reichert, Charles A. Lesburg, Vincent S. Madison, Kuo-Chi Cheng
-
Publication number: 20080199447Abstract: The present invention discloses purified polypeptides that comprise an active ADAM33 catalytic domain. In addition, the present invention discloses nucleic acids that encode the polypeptides of the present invention. The present invention also discloses methods of growing X-ray diffractable crystals of polypeptides comprising the active ADAM33 catalytic domain. In addition, the present invention discloses methods of using the X-ray diffractable crystals of ADAM33 in structure-based drug design to identify compounds that can modulate the enzymatic activity of ADAM33. The present invention also discloses methods of treating respiratory disorders by administering therapeutic amounts of the ADAM33 catalytic domain.Type: ApplicationFiled: December 20, 2007Publication date: August 21, 2008Inventors: Wenyan Wang, Hung V. Le, Jian-Jun Liu, Vincent S. Madison, Winifred W. Prosise, Shahriar Shane Taremi, Li Xiao, Jun Zou
-
Patent number: 7335758Abstract: The present invention discloses purified polypeptides that comprise an active ADAM33 catalytic domain. In addition, the present invention discloses nucleic acids that encode the polypeptides of the present invention. The present invention also discloses methods of growing X-ray diffractable crystals of polypeptides comprising the active ADAM33 catalytic domain. In addition, the present invention discloses methods of using the X-ray diffractable crystals of ADAM33 in structure-based drug design to identify compounds that can modulate the enzymatic activity of ADAM33. The present invention also discloses methods of treating respiratory disorders by administering therapeutic amounts of the ADAM33 catalytic domain.Type: GrantFiled: October 2, 2006Date of Patent: February 26, 2008Assignee: Schering CorporationInventors: Wenyan Wang, Hung V. Le, Jian-Jun Liu, Vincent S. Madison, Winifred W. Prosise, Shahriar Shane Taremi, Li Xiao, Jun Zou
-
Patent number: 7208311Abstract: The present invention discloses purified polypeptides that comprise an active ADAM33 catalytic domain. In addition, the present invention discloses nucleic acids that encode the polypeptides of the present invention. The present invention also discloses methods of growing X-ray diffractable crystals of polypeptides comprising the active ADAM33 catalytic domain. In addition, the present invention discloses methods of using the X-ray diffractable crystals of ADAM33 in structure-based drug design to identify compounds that can modulate the enzymatic activity of ADAM33. The present invention also discloses methods of treating respiratory disorders by administering therapeutic amounts of the ADAM33 catalytic domain.Type: GrantFiled: December 19, 2003Date of Patent: April 24, 2007Assignee: Schering CorporationInventors: Wenyan Wang, Hung V. Le, Jian-Jun Liu, Vincent S. Madison, Winifred W. Prosise, Shahriar Shane Taremi, Li Xiao, Jun Zou
-
Publication number: 20040151715Abstract: The present invention discloses purified polypeptides that comprise an active ADAM33 catalytic domain. In addition, the present invention discloses nucleic acids that encode the polypeptides of the present invention. The present invention also discloses methods of growing X-ray diffractable crystals of polypeptides comprising the active ADAM33 catalytic domain. In addition, the present invention discloses methods of using the X-ray diffractable crystals of ADAM33 in structure-based drug design to identify compounds that can modulate the enzymatic activity of ADAM33. The present invention also discloses methods of treating respiratory disorders by administering therapeutic amounts of the ADAM33 catalytic domain.Type: ApplicationFiled: December 19, 2003Publication date: August 5, 2004Applicant: Schering CorporationInventors: Wenyan Wang, Hung V. Le, Jian-Jun Liu, Vincent S. Madison, Winifred W. Prosise, Shahriar Shane Taremi, Li Xiao, Jun Zou
-
Patent number: 6524589Abstract: The invention relates to the purification and crystallization of hepatitis C virus (HCV) NS3/NS4A polypeptide complex. Also, crystallization conditions for NS3/NS4A are provided. Further, the atomic coordinates for the NS3/NS4A protein are disclosed. Examples of its use for the determination of the three-dimensional atomic structures of HCV NS3/NS4A with substrate(s) or substrate analog(s) or inhibitor complexes are also provided.Type: GrantFiled: April 5, 2000Date of Patent: February 25, 2003Assignee: Schering CorporationInventors: Paul Reichert, Winifred W. Prosise, Shahriar Shane Taremi, Nanhua Yao, Patricia C. Weber
-
Patent number: 5981167Abstract: A method for determining if an enzyme can cleave a substrate or if a substance is an inhibitor of the enzyme using surface plamon resonance.Type: GrantFiled: February 10, 1998Date of Patent: November 9, 1999Inventors: Shahriar Shane Taremi, Winifred W. Prosise